ALCJ

Crossject (ALCJ)

Crossject

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:ALCJ

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/24	01:00	GlobeNewswire Inc.	Crossject reports financial results and business highlights for the first six months of 2024	EU:ALCJ	Crossject
2024/08/22	14:30	GlobeNewswire Inc.	Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024	EU:ALCJ	Crossject
2024/08/20	00:30	GlobeNewswire Inc.	Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment	EU:ALCJ	Crossject
2024/07/18	14:30	GlobeNewswire Inc.	Crossject achieves key ZEPIZURE® manufacturing milestone	EU:ALCJ	Crossject
2024/07/15	14:30	GlobeNewswire Inc.	Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference	EU:ALCJ	Crossject
2024/07/10	14:30	GlobeNewswire Inc.	Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine	EU:ALCJ	Crossject
2024/07/05	17:09	GlobeNewswire Inc.	Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social	EU:ALCJ	Crossject
2024/06/26	14:30	GlobeNewswire Inc.	Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	EU:ALCJ	Crossject
2024/06/26	14:30	GlobeNewswire Inc.	Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	EU:ALCJ	Crossject
2024/06/26	14:30	GlobeNewswire Inc.	Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.	EU:ALCJ	Crossject
2024/06/18	19:30	GlobeNewswire Inc.	Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social	EU:ALCJ	Crossject
2024/06/13	16:36	GlobeNewswire Inc.	Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social	EU:ALCJ	Crossject
2024/06/12	14:30	GlobeNewswire Inc.	Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	EU:ALCJ	Crossject
2024/06/12	14:30	GlobeNewswire Inc.	Crossject appoints Dan Chiche, MD as Chief Medical Officer North America	EU:ALCJ	Crossject
2024/06/12	14:30	GlobeNewswire Inc.	Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord	EU:ALCJ	Crossject
2024/06/05	02:30	GlobeNewswire Inc.	Crossject announces highly successful closing of its €8 million rights offering	EU:ALCJ	Crossject
2024/06/05	02:30	GlobeNewswire Inc.	Crossject announces highly successful closing of its €8 million rights offering	EU:ALCJ	Crossject
2024/06/05	02:30	GlobeNewswire Inc.	Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros	EU:ALCJ	Crossject
2024/05/30	17:30	GlobeNewswire Inc.	Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy	EU:ALCJ	Crossject
2024/05/30	17:30	GlobeNewswire Inc.	Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy	EU:ALCJ	Crossject
2024/05/30	17:30	GlobeNewswire Inc.	Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy	EU:ALCJ	Crossject
2024/05/03	00:30	GlobeNewswire Inc.	Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe	EU:ALCJ	Crossject
2024/05/03	00:30	GlobeNewswire Inc.	Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe	EU:ALCJ	Crossject
2024/05/03	00:30	GlobeNewswire Inc.	Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en Europe	EU:ALCJ	Crossject
2024/05/01	02:05	GlobeNewswire Inc.	Crossject annonce le lancement d’une augmentation de capital	EU:ALCJ	Crossject
2024/04/25	14:32	GlobeNewswire Inc.	Crossject reports audited financial results for 2023	EU:ALCJ	Crossject
2024/04/25	14:32	GlobeNewswire Inc.	Crossject reports audited financial results for 2023	EU:ALCJ	Crossject
2024/04/25	14:32	GlobeNewswire Inc.	Crossject communique ses résultats financiers audités pour 2023	EU:ALCJ	Crossject
2024/04/10	23:30	GlobeNewswire Inc.	Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social	EU:ALCJ	Crossject
2024/04/03	01:35	GlobeNewswire Inc.	Crossject trading on Euronext to resume as usual on Wednesday April 3	EU:ALCJ	Crossject